Access to Medicines Archives – Page 3 of 7

Let’s Talk! HIV Vaccines 101

May 19, 2022
Dorrit Walsh

On May 18, 2022, Treatment Action Group (TAG), the Black AIDS Institute (BAI), and the Southern AIDS Coalition (SAC) participated in this fun and informative Instagram Live discussion commemorating HIV Vaccine Awareness. Day.

Joint Statement from Leading HIV/AIDS and Viral Hepatitis Advocates regarding Manufacturer Action on the 340B Drug Pricing Program

April 20, 2022
Dorrit Walsh

A group of six leading HIV/AIDS and viral hepatitis advocates today released the following joint statement regarding recent manufacturer action against the 340B Drug Pricing Program:

The Right to Prevent TB

March 17, 2022
Dorrit Walsh

It’s now easier than ever to prevent TB before it develops into active disease or spreads within communities.

Statement from TAG’s HIV Project on FDA’s Approval of Injectable Pre-Exposure Prophylaxis

December 22, 2021
Dorrit Walsh

Treatment Action Group (TAG) welcomes and celebrates the U.S. Food and Drug Administration’s (FDA) approval of Apretude brand cabotegravir, the first injectable medication for use as pre-exposure prophylaxis (PrEP) to reduce the risk of HIV transmission.

Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis of Patenting Trends and Implications for Access

November 4, 2021
Dorrit Walsh

This new report offers recommendations to ensure access to long-acting technologies throughout the research and development process.

Delivering on the Promise of Long-Acting Technologies

October 3, 2021
Dorrit Walsh

By Susan Swindells* and Mark Harrington This issue of TAGline explores the exciting opportunities and challenges that come with the development of long-acting formulations for the prevention and treatment of infectious diseases. For many years to date, patients and providers…

first page of TAG and MSF brief: Realizing returns on U.S. government investment in GeneXpert Diagnostic Technologies

Realizing Returns on U.S. Government Investments in GeneXpert Diagnostic Technologies

September 15, 2021
Dorrit Walsh

GeneXpert diagnostic tests are essential tools in the struggle against COVID-19, tuberculosis, HIV, viral hepatitis, and other diseases. This brief outlines actionable steps the U.S. government can take to hold Cepheid accountable for transparent, fair, and equitable pricing of GeneXpert tests.

Have a Heart, Save My Liver! Who Has Access to the Cure in Africa?

September 11, 2021
Dorrit Walsh

On September 11 2021, Treatment Action Group’s Joelle Dountio Ofinboudem presented new data on the registration of the hepatitis C cure at the Conference on Liver Disease in Africa (COLDA) 2021. The presentation titled, “Have a Heart, Save My Liver! Who Has Access to the Cure in Africa,” explains that accelerating treatment uptake across Africa is urgently needed to meet WHO hepatitis C targets by 2030.

TAG Urges Governor to Sign New York State Bill Expanding Adult Vaccines Available in Pharmacies

June 3, 2021
Dorrit Walsh

The bill, S4807A (Stavisky) / A6476A (Hyndman), improves preventive viral hepatitis vaccine access, and is particularly important for people who use drugs and unhoused New Yorkers.

Community Engagement on TB through Storytelling

May 24, 2021
Dorrit Walsh

Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. These storyboards follow three individuals journeys through diagnosis, treatment and care, and the barriers they face.